Crossmark

Dose optimization of omadacycline for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD) using a physiologically based pharmacokinetic modeling approach

Crossref DOI link: https://doi.org/10.1007/s40005-025-00776-0

Published Online: 2025-10-13

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Heo, Dong-Gyu

Sanders, Madeline

de Moura, Vinicius Calado Nogueira

Daley, Charles L.

Beringer, Paul M.

Hong, Eunjin https://orcid.org/0000-0002-6696-3948
Funding

Funding for this research was provided by:

NIH/NIDCR training (T90-DE02198213)

Anton Yelchin Foundation (N/A)
License Information

Text and Data Mining valid from 2025-10-13

Version of Record valid from 2025-10-13
More Information

Article History

Received: 19 July 2025

Accepted: 28 September 2025

First Online: 13 October 2025

Declarations

:

: Not applicable.

: This article does not contain any studies with human and animal subjects performed by any of the authors.

: All authors (D.G. Heo, M. Sanders, V.C.N. de Moura, C.L. Daley, P.M. Beringer, and E. Hong) declare that they have no conflict of interest.

Document is current

Any future updates will be listed below